简介:目的应用新型泪道引流管治疗泪小管断裂,恢复泪道引流通路.方法对30例泪小管断裂患者使用新型泪道引流管作为支撑管行泪小管吻合术,将引流的两端探子分别从上、下泪点插入泪道,通过泪管断端经过鼻泪管至下鼻道开口处,在鼻腔内窥镜直视下,用镊子触及并取出探子于鼻腔外,在探子与硅胶管交界处剪断硅胶管,两端硅胶管在鼻腔内打结留置于鼻腔.术后3月或0.5a拔管.并与以往用硬膜外麻醉管做支架的疗效进行比较.结果30例患者均于植管后3~7d内症状消失,29例拔管后达到治愈标准,无泪管豁开、下睑外翻或泪点外翻等并发症.治疗效果明显优于以硬膜外麻醉管作支架管吻合组.结论新型泪道引流管作为泪小管断裂吻合支撑管,伤口愈合快,成功率高,值得推广使用.
简介:目的:探讨玻璃体腔注射贝伐单抗(bevacizumab)联合Ex-press青光眼引流管植入术治疗新生血管性青光眼的疗效和安全性。方法:对18例19眼新生血管性青光眼患者,先行玻璃体腔注射bevacizumab,待虹膜新生血管消退或萎缩后,再行Ex-press青光眼引流管(P-200)植入术,其中6例6眼联合超声乳化白内障吸除术。根据患者屈光介质情况术前或术后尽量行全视网膜光凝。Ex-press植入术后随访12mo,观察视力、眼压和手术并发症情况。结果:玻璃体腔注药后2~7d,16眼新生血管全部消退。术后平均眼压:1mo:13.05±2.46mmHg,3mo:13.80±1.88mmHg,6mo:14.30±1.38mmHg;12mo:14.60±1.43mmHg,术后1,3,6,12mo眼压与术前相比均有显著性差异(P<0.05),且术后1,3,6,12mo眼压相比均无显著性差异(P>0.05)。19眼术后视力有提高者4眼,无明显改变15眼,无视力下降眼,完全成功11眼(58%),部分成功5眼(26%),总手术成功率84%(16/19)。术后并发症:有2例术后早期短暂浅前房,散瞳1wk后前房恢复正常,1例前房少量积血,无排斥反应和严重并发症。结论:玻璃体腔注射bevacizumab可使新生血管青光眼虹膜新生血管迅速消退或萎缩,为下一步青光眼手术创造良好的条件。Ex-press青光眼引流管植入术是新的滤过性手术,该手术创伤小,不用切除虹膜,减少了术中、术后出血的风险,联合bevacizumab是治疗新生血管性青光眼的安全而有效的术式。
简介:目的探讨数字化多媒体系统矫治训练对大龄儿童弱视的治疗效果。方法选取2013年1月至2016年1月我院门诊收治的大龄弱视患儿86例(128眼),作为研究对象。根据患儿治疗方案的差异将其分为观察组与对照组,对照组45例患儿接受常规综合治疗措施,观察组41例患儿接受数字化多媒体系统治疗,比较两组患儿治疗后双眼视功能变化及疗效。结果观察组患儿治疗后总有效率明显高于对照组,并且观察组患者立体视改善率明显高于对照组,P〈0.05,差异具有统计学意义。结论对大龄弱视患儿采取数字化多媒体系统治疗可有效改善患儿弱视症状,提高患儿双眼视功能,缩短患儿视功能障碍治疗时间,具有临床应用及推广价值。
简介:·Thisisacasepresentationofaverybizarreopenglobetraumawithanteriorsegmentforeignbody-fishinghookstuckinthecorneaandiris.Complicationsduetothiskindofeyetraumamightbeveryhazardousandwithseriousimpactonvisualfunction.Wearerepresentingourapproachandexperienceofthreestepmanagementofthiskindofeyeinjury:first-extracttheforeignbody,closeandreconstructtheeyeball,second-fightinflammation,andthird-restorethevisualfunctionbycataractsurgery.·
简介:AIM:Tocomparetheeffectoftopicallyadministeredandsubconjunctivallyinjectedbevacizumabonexperimentalcornealneovascularizationinratsfortwoweeksaftertreatment.METHODS:Twenty-eightSprague-Dawleyratsweredividedintofourgroupsof7animals.Eachcornealcenterofrighteyewascauterizedwithsilver/potassiumnitratefor8s.Aftercornealburning,bevacizumab(12.5mg/mL)wastopicallyadministeredthreetimesperday(TBgroup)fortwoweeksorsubconjunctivallyinjectedondays2and4aftercauterization(0.02mL;SBgroup).Asnegativecontrols,ratsreceived0.9%salinetopicallythreetimesperday(TSgroup)orsubconjunctivallyondays2and4(0.02mL;SSgroup).Digitalphotographsofthecorneaweretaken1and2weeksaftertreatmentandanalyzedtodeterminetheareaofcorneacoveredbyneovascularizationasthepercentageofcornealneovascularization.RESULTS:Oneweekaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBandSBgroupsthanintheTSandSSgroups(allP<0.05).Twoweeksaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBgroupthanintheTSgroup(P<0.05).Inallgroups,thepercentageofneovascularizationwasdecreasingastimepassed(allP<0.05)CONCLUSION:Topicallyadministeredbevacizumabhaslongerstandinganti-angiogeniceffectthansubconjunctivallyinjectedbevacizumabincornealneovascularizationfollowingchemicalinjuryinrats.